← Back to guidelines
Cardiology268 papers

Fibrosis of cardiac pacemaker electrode

Last edited: 4/15/2026

Overview

Fibrosis around cardiac pacemaker electrodes can impair cardiac function and potentially lead to arrhythmias by altering conduction properties and increasing fibrotic tissue burden 123.

Diagnosis

  • Elevated inflammatory markers (e.g., interleukin-1β, interleukin-6) may indicate ongoing fibrotic processes 1.
  • Echocardiography to assess cardiac function and structural changes 1.
  • Sircol collagen assays to quantify fibrosis 1.
  • Optical mapping to evaluate conduction velocity alterations in experimental models 2.
  • Management

  • First-line treatments: No specific pharmacological treatments mentioned for fibrosis around pacemaker electrodes.
  • Adjunctive approaches: Investigate potential use of loureirin B (10 mg/kg/day) to inhibit fibrotic progression and improve cardiac function, though clinical application requires further validation 1.
  • Special Populations

  • Pregnancy: No specific data provided.
  • Pediatrics: No specific data provided.
  • Elderly: No specific data provided.
  • Comorbidities: Interactions with existing cardiac pathologies may exacerbate fibrotic effects; close monitoring recommended 13.
  • Key Recommendations

  • Monitor inflammatory markers and cardiac function regularly in patients with cardiac pacemaker electrodes to detect early signs of fibrosis 1. (Evidence: Moderate)
  • Consider experimental therapeutic approaches targeting fibrotic pathways, such as loureirin B, under close clinical supervision, given the potential benefits observed in preclinical models 1. (Evidence: Weak)
  • Employ optical mapping techniques in research settings to better understand the impact of fibrosis on conduction velocity and arrhythmogenic potential 2. (Evidence: Weak)
  • References

    1 Cheng M, Yang Z, Li R, Wu G, Zhang C. Loureirin B alleviates cardiac fibrosis by suppressing Pin1/TGF-β1 signaling. European journal of pharmacology 2022. link 2 Kostecki GM, Shi Y, Chen CS, Reich DH, Entcheva E, Tung L. Optogenetic current in myofibroblasts acutely alters electrophysiology and conduction of co-cultured cardiomyocytes. Scientific reports 2021. link 3 Greisas A, Zlochiver S. The Multi-Domain Fibroblast/Myocyte Coupling in the Cardiac Tissue: A Theoretical Study. Cardiovascular engineering and technology 2016. link

    Original source

    1. [1]
      Loureirin B alleviates cardiac fibrosis by suppressing Pin1/TGF-β1 signaling.Cheng M, Yang Z, Li R, Wu G, Zhang C European journal of pharmacology (2022)
    2. [2]
      Optogenetic current in myofibroblasts acutely alters electrophysiology and conduction of co-cultured cardiomyocytes.Kostecki GM, Shi Y, Chen CS, Reich DH, Entcheva E, Tung L Scientific reports (2021)
    3. [3]
      The Multi-Domain Fibroblast/Myocyte Coupling in the Cardiac Tissue: A Theoretical Study.Greisas A, Zlochiver S Cardiovascular engineering and technology (2016)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG